IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v24y2023i3d10.1007_s10198-022-01463-9.html
   My bibliography  Save this article

Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study

Author

Listed:
  • Antoine Bessou

    (IQVIA)

  • Xavier Colin

    (GlaxoSmithKline)

  • Julie De Nascimento

    (IQVIA)

  • Will Sopwith

    (IQVIA)

  • Shannon Ferrante

    (Value Evidence and Outcomes, GlaxoSmithKline)

  • Boris Gorsh

    (Value Evidence and Outcomes, GlaxoSmithKline)

  • Benjamin Gutierrez

    (Value Evidence and Outcomes, GlaxoSmithKline)

  • Leah Sansbury

    (Value Evidence and Outcomes, GlaxoSmithKline)

  • Jenny Willson

    (Value Evidence and Outcomes, GlaxoSmithKline)

  • Sandhya Sapra

    (Value Evidence and Outcomes, GlaxoSmithKline)

  • Prani Paka

    (Global Medical Affairs, GlaxoSmithKline)

  • Feng Wang

    (Value Evidence and Outcomes, GlaxoSmithKline)

Abstract

Background Real-world data on health care resource utilisation (HCRU) and costs for French patients with multiple myeloma (MM) are limited due to the quickly evolving MM treatment landscape. This retrospective, national-level study quantified the MM economic burden in France. Methods The study included patients with newly diagnosed MM from the Système National des Données de Santé coverage claims database between 2013 and 2018 who received active treatment within 30 days of diagnosis. HCRU included hospitalisations, drugs, consultations, procedures, tests, devices, transport, and sick leave. Costs were annualized to 2019 prices. Drug treatments, reported by line of therapy (LOT), were algorithmically defined using drug regimen, duration of therapy, and gaps between treatments. Analyses were stratified by stem cell transplantation status and LOT. Results Among 6413 eligible patients, 6229 (97.1%) received ≥ 1 identifiable LOT; most received 1 (39.8%) or 2 LOT (27.5%) during follow-up. Average annual hospitalisation was 6.3 episodes/patient/year (median duration: 11.6 days). The average annual cost/patient was €58.3 K. Key cost drivers were treatment (€28.2 K; 39.5% of total HCRU within one year of MM diagnosis) and hospitalisations (€22.2 K; 48.6% of total HCRU costs in first year). Monthly treatment-related costs increased from LOT1 (€2.447 K) and LOT5 + (€7.026 K); only 9% of patients received LOT5 + . At LOT4 + , 37 distinct regimens were identified. Hospitalisation costs were higher in patients with stem cell transplantation than total population, particularly in the first year. Conclusions This study showed a high economic burden of MM in France (€72.37 K/patient/year in the first year) and the diversity of regimens used in late-line treatments.

Suggested Citation

  • Antoine Bessou & Xavier Colin & Julie De Nascimento & Will Sopwith & Shannon Ferrante & Boris Gorsh & Benjamin Gutierrez & Leah Sansbury & Jenny Willson & Sandhya Sapra & Prani Paka & Feng Wang, 2023. "Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective co," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 321-333, April.
  • Handle: RePEc:spr:eujhec:v:24:y:2023:i:3:d:10.1007_s10198-022-01463-9
    DOI: 10.1007/s10198-022-01463-9
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-022-01463-9
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s10198-022-01463-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Manuel Neves & Fernanda Trigo & Bergantim Rui & Cristina João & Paulo Lúcio & Neves Mariana & João Mendes & Hugo Pedrosa & Catarina Geraldes, 2021. "Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness," PharmacoEconomics, Springer, vol. 39(5), pages 579-587, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Zeki Kocaata & Thomas Wilke & Franz Fischer & Robert Welte & Hermann Einsele, 2022. "Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis," PharmacoEconomics - Open, Springer, vol. 6(4), pages 619-628, July.
    2. Jacopo Garlasco & Mario Cesare Nurchis & Valerio Bordino & Martina Sapienza & Gerardo Altamura & Gianfranco Damiani & Maria Michela Gianino, 2022. "Cancers: What Are the Costs in Relation to Disability-Adjusted Life Years? A Systematic Review and Meta-Analysis," IJERPH, MDPI, vol. 19(8), pages 1-17, April.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:24:y:2023:i:3:d:10.1007_s10198-022-01463-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.